Heart Failure Stat! -
Driving Inpatient Efficiency:
The Hospitalist's Guide to Acute Decompensated
Heart Failure

Duration: 2 hours
Date of Original Release: June 2008
Live Event: April 5, 2008
(satellite symposium)
Expiration Date: June 2009
Type of Media Used: Online
HTML Webcast

 

 

 

Jointly sponsoed by the Postgraduate Institute for Medicine and SynerMed Communications. Supported by an educational grant from Scios.

References

Abraham WT. Nesiritide and mortality risk: individual and pooled analyses of randomized controlled trials. Rev Cardiovasc Med. 2005;6:2.

Acute Decompensated Heart Failure National Registry (ADHERE). Acute Decompensated Heart Failure National Registry: 3rd quarter 2003 national benchmark report. http://www.adhereregistry.com/national_ BMR/Q3_2003_ADHERE_National_BMR.pdf. Accessed January 7, 2005.

Adams KF, Lindenfeld J, Arnold JM, et al. HFSA 2006 Comprehensive Heart Failure Practice Guidelines. J Card Fail. 2006;12:e1-e119.

Aggarwal A, Esler MD, Morris MJ, Lambert G, Kaye DM. Regional sympathetic effects of low-dose clonidine in heart failure. Hypertension. 2003;41(3):553-557.

Akhter MW, Singh H, Bourji N, et al. Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure. Circulation. 2004;110(suppl III):556.

Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation. 2004;110(15):2168-2174.

Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide: the level and the drug-partners in the diagnosis and management of congestive heart failure. Congest Heart Fail. 2004;10(suppl 1):S3-S27.

Burger AJ. Clinical predictors of worsening renal function in patients hospitalized for heart failure. Paper presented at: Heart Failure Society of America 9th Annual Scientific Sessions; September 19, 2005; Boca Raton, FL.

Butler J, Emerman C, Peacock WF, Mathur VS, Young JB. The efficacy and safety of B-type natriuretic peptide (nesiritide) in patients with renal insufficiency and acutely decompensated congestive heart failure. Nephrol Dial Transplant. 2004;19(2):391-399.

Chin BS, Conway DS, Chung NA, Blann AD, Gibbs CR, Lip GY. Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: relationship to treatment and prognosis. Blood Coagul Fibrinolysis. 2003;14(6):515-521.

Colucci WS, Elkayam U, Horton DP, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med. 2000;343(4):246-253.

Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol. 2006;97(12):1759-1764.

Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50(8):768-777.

Fonarow GC, Adams KF, Jr., Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. Jama. 2005;293(5):572-580.

Fonarow GC, Peacock WF, Horwich TB, et al. Usefulness of B-type natriuretic peptide and cardiac troponin levels to predict in-hospital mortality from ADHERE. Am J Cardiol. 2008;101(2):231-237.

Fonarow GC, Yancy CW, Heywood JT. Adherence to heart failure quality-of-care indicators in US hospitals: analysis of the ADHERE Registry. Arch Intern Med. 2005;165(13):1469-1477.

Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol. 2004;43(1):61-67.

Francis GS, Siegel RM, Goldsmith SR, Olivari MT, Levine TB, Cohn JN. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103(1):1-6.

Gottlieb SS, Brater DC, Thomas I, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation. 2002;105(11):1348-1353.

Green SM, Redmond P, Januzzi JL, et al. The impact of amino-terminal pro-brain natriuretic peptide testing on hospital length of stay and morbidity in patients with acute decompensated heart failure. Arch Pathol Lab Med. 2007;131(3):473-476.

Harjai KJ, Dinshaw HK, Nunez E, et al. The prognostic implications of outpatient diuretic dose in heart failure. Int J Cardiol. 1999;71(3):219-225.

Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail. 2007;13(6):422-430.

Hugli O, Braun JE, Kim S, Pelletier AJ, Camargo CA, Jr. United States emergency department visits for acute decompensated heart failure, 1992 to 2001. Am J Cardiol. 2005;96(11):1537-1542.

Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. Jama. 2002;287(12):1531-1540.

Jain P, Massie BM, Gattis WA, Klein L, Gheorghiade M. Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am Heart J. 2003;145(2 suppl):S3-S17.

Koelling TM, Johnson ML, Cody RJ, Aaronson KD. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation. 2005;111(2):179-185.

Lee CR, Watkins ML, Patterson JH, et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J. 2003;146(1):9-18.

Liang KV, Hiniker AR, Williams AW, Karon BL, Greene EL, Redfield MM. Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center. J Card Fail. 2006;12(9):707-714.

Maisel A. B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient. Rev Cardiovasc Med. 2002;3(suppl 4):S10-S17.

Marcus LS, Hart D, Packer M, et al. Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation. 1996;94(12):3184-3189.

Mentzer RM, Jr, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA trial. J Am Coll Cardiol. 2007;49(6):716-726.

Moe GW, Rouleau JL, Nguyen QT, Cernacek P, Stewart DJ. Role of endothelins in congestive heart failure. Can J Physiol Pharmacol. 2003;81(6):588-597.

Natrecor® [prescribing information]. Freemont, CA: Scios Inc; April 2005. http://www.sciosinc.com/pdf/natrecorpi_final.pdf. Accessed May 28, 2008

Nieminen MS, Bohm M, Cowie MR, et al. Executive summary of the Guidelines on the Diagnosis and Treatment of Acute Heart Failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26(4):384-416.

Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal Interactions. J Am Coll Cardiol. 2008; 51(13):1268-74.

Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002;287(5):628-640.

Peacock WF, Emerman CL, Silver MA. Nesiritide added to standard care favorably reduces systolic blood pressure compared with standard care alone in patients with acute decompensated heart failure. Am J Emerg Med. 2005;23(3):327-331.

Peacock WF 4th, Holland R, Gyarmathy R, et al. Observation unit treatment of heart failure with nesiritide: results from the PROACTION trial. J Emerg Med. 2005;29(3):243-252.

Porter KE, Turner NA, O'Regan DJ, Ball SG. Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res. 2004;64(3):507-515.

Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke statistics 2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117(4):e25-146.

Sackner-Bernstein JD, Skopicki H, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acute decompensated heart failure. Circulation. 2005;111:1487-1491.

Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2005(3):CD003178.

Shah M, Ali V, Lamba S, Abraham WT. Pathophysiology and clinical spectrum of acute congestive heart failure. Rev Cardiovasc Med. 2001;2(suppl 2):S2-S6.

Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes. Ann Emerg Med. 2007;49(5):627-669.

Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92(6):1487-1493.

Wang DJ, Dowling TC, Meadows D, et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation. 2004;110(12):1620-1625.

Wang DJ, Gottlieb SS. Diuretics: still the mainstay of treatment. Crit Care Med. 2008;36(1 Suppl):S89-94.

Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 1999;138 (2 Pt 1):285-290.

Witteles RM, Kao D, Christopherson D, et al. Impact of nesiritide on renal function in patients with acute decompensated heart failure and pre-existing renal dysfunction a randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol. 2007;50(19):1835-1840.

Zakir RM, Patel RJ, Saric M, Berkowitz RL. Nesiritide is effective for patients with diastolic dysfunction with and without associated right ventricular failure and significantly improves renal function. Paper presented at: Heart Failure Society of America 9th Annual Scientific Sessions, September 19, 2005; Boca Raton, FL.